Bank Hapoalim BM lowered its holdings in shares of Edwards Lifesciences Corp (NYSE:EW) by 29.2% in the first quarter, HoldingsChannel.com reports. The firm owned 2,450 shares of the medical research company’s stock after selling 1,010 shares during the period. Bank Hapoalim BM’s holdings in Edwards Lifesciences were worth $469,000 as of its most recent filing with the SEC.
Other institutional investors have also bought and sold shares of the company. FTB Advisors Inc. acquired a new stake in Edwards Lifesciences during the first quarter worth approximately $25,000. Executive Wealth Management LLC acquired a new stake in Edwards Lifesciences during the fourth quarter worth approximately $25,000. Sontag Advisory LLC acquired a new stake in Edwards Lifesciences during the fourth quarter worth approximately $26,000. Field & Main Bank acquired a new stake in Edwards Lifesciences during the first quarter worth approximately $34,000. Finally, Lindbrook Capital LLC acquired a new stake in Edwards Lifesciences during the fourth quarter worth approximately $27,000. Institutional investors and hedge funds own 84.43% of the company’s stock.
In other Edwards Lifesciences news, CEO Michael A. Mussallem sold 32,800 shares of the business’s stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $167.89, for a total transaction of $5,506,792.00. Following the completion of the transaction, the chief executive officer now directly owns 67,126 shares in the company, valued at $11,269,784.14. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Larry L. Wood sold 6,716 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $170.82, for a total transaction of $1,147,227.12. Following the transaction, the vice president now owns 122,366 shares of the company’s stock, valued at $20,902,560.12. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 148,411 shares of company stock valued at $26,189,586. Company insiders own 1.63% of the company’s stock.
Several equities research analysts have issued reports on EW shares. Cowen restated a “buy” rating on shares of Edwards Lifesciences in a research report on Monday, February 4th. Stifel Nicolaus reiterated a “buy” rating and issued a $190.00 price target on shares of Edwards Lifesciences in a research report on Sunday, February 3rd. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and lifted their price target for the company from $180.00 to $190.00 in a research report on Friday, January 18th. Canaccord Genuity reiterated a “buy” rating and issued a $215.00 price target (up from $190.00) on shares of Edwards Lifesciences in a research report on Monday, March 18th. Finally, Jefferies Financial Group lifted their price target on shares of Edwards Lifesciences from $195.00 to $210.00 and gave the company a “buy” rating in a research report on Wednesday, April 24th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and fourteen have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $187.00.
NYSE EW opened at $178.89 on Thursday. Edwards Lifesciences Corp has a 1-year low of $134.38 and a 1-year high of $197.86. The company has a market capitalization of $37.20 billion, a PE ratio of 38.06, a price-to-earnings-growth ratio of 2.28 and a beta of 0.85. The company has a debt-to-equity ratio of 0.17, a current ratio of 3.66 and a quick ratio of 2.69.
Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Tuesday, April 23rd. The medical research company reported $1.32 EPS for the quarter, beating the consensus estimate of $1.23 by $0.09. Edwards Lifesciences had a net margin of 20.03% and a return on equity of 31.16%. The business had revenue of $993.00 million during the quarter, compared to the consensus estimate of $989.87 million. During the same period in the previous year, the business earned $1.22 earnings per share. The company’s revenue was up 11.0% on a year-over-year basis. On average, sell-side analysts anticipate that Edwards Lifesciences Corp will post 5.28 earnings per share for the current year.
Edwards Lifesciences Profile
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.
See Also: What are the FAANG Stocks?
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.